Literature DB >> 2153442

Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study.

P F Daly1, G Zugmaier, D Sandler, M Carpen, C E Myers, J S Cohen.   

Abstract

Using 31P nuclear magnetic resonance spectroscopy we have noninvasively observed metabolic control through the cytidine pathways of phosphatidylcholine and phosphatidylethanolamine synthesis in intact actively metabolizing MDA-MB-231 human breast cancer cells. Perfusion with the phospholipid precursors ethanolamine or choline (2 mM) indicates that the cytidylyltransferase enzymes are rate limiting for both pathways. Complete inhibition of choline kinase with ethanolamine allowed the observation of the utilization of phosphocholine by the rate-limiting enzyme choline-phosphate cytidylyltransferase. The rate was dependent on the phosphocholine concentration. Inhibition of glycerophosphorylcholine phosphodiesterase with accumulation of substrate was also observed and allows an estimate of the flux through the degradative pathways. The human lymphoma cell line MOLT-4 was also found to contain high levels of phosphocholine and phosphoethanolamine. The levels of these precursors in the MOLT-4 line are lowered by 40% after 6 h when perfused with high dose 1-beta-D-arabinofuranosylcytosine (Ara-C) (400 microns) but are unaffected by 2 microns Ara-C or dideoxycytidine. High dose Ara-C also resulted in lysis in 8-10 h. However, the MDA-MB-231 cell line which is not sensitive to Ara-C showed no change in its spectrum when perfused with Ara-C. A potential mechanism based on classic phospholipid metabolism for the lytic effect of high dose Ara-C is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153442

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 2.  MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions.

Authors:  Marie-France Penet; Tariq Shah; Flonne Wildes; Balaji Krishnamachary; Santosh K Bharti; Jesus Pacheco-Torres; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2019-01-28       Impact factor: 4.044

Review 3.  The versatility of the CD1 lipid antigen presentation pathway.

Authors:  Andrew Chancellor; Stephan D Gadola; Salah Mansour
Journal:  Immunology       Date:  2018-03-24       Impact factor: 7.397

4.  CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b+ T cell lymphoma.

Authors:  Sreya Bagchi; Sha Li; Chyung-Ru Wang
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110

Review 5.  Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies.

Authors:  O Kaplan; J S Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Effects of Novel Dinuclear Cisplatinum(II) Complexes on the Electrical Properties of Human Molt-4 Leukemia Cells.

Authors:  Izabela Dobrzyńska; Elżbieta Skrzydlewska; Zbigniew A Figaszewski
Journal:  Cell Biochem Biophys       Date:  2015-04       Impact factor: 2.194

7.  Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.

Authors:  Nizar Serhan; Pierre-Luc Mouchel; Philippe de Medina; Gregory Segala; Aurélie Mougel; Estelle Saland; Arnaud Rives; Antonin Lamaziere; Gaëtan Despres; Jean-Emmanuel Sarry; Clément Larrue; François Vergez; Laetitia Largeaud; Michel Record; Christian Récher; Sandrine Silvente-Poirot; Marc Poirot
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

8.  31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance.

Authors:  R Tausch-Treml; P Köpf-Maier; F Baumgart; B Gewiese; D Ziessow; H Scherer; K J Wolf
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

9.  Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Authors:  T E Bapiro; K K Frese; A Courtin; J L Bramhall; B Madhu; N Cook; A Neesse; J R Griffiths; D A Tuveson; D I Jodrell; F M Richards
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.